dasatinib
Selected indexed studies
- Dasatinib. (Profiles Drug Subst Excip Relat Methodol, 2014) [PMID:24794907]
- Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. (Clin Lymphoma Myeloma Leuk, 2017) [PMID:28082112]
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. (J Clin Oncol, 2016) [PMID:27217448]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Dasatinib. (2014) pubmed
- Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management. (2017) pubmed
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. (2016) pubmed
- Pharmacokinetics of Dasatinib. (2019) pubmed
- Dasatinib. (2014) pubmed
- Dasatinib-induced pulmonary arterial hypertension. (2018) pubmed
- Dasatinib-induced Chylothorax in Chronic Myeloid Leukemia. (2022) pubmed
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. (2019) pubmed
- Dasatinib-induced Crohn's-like colitis. (2023) pubmed
- Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit. (2021) pubmed